Zacks Investment Research lowered shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a buy rating to a hold rating in a research report sent to investors on Thursday morning.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
A number of other brokerages have also issued reports on APTO. ValuEngine upgraded shares of Aptose Biosciences from a strong sell rating to a sell rating in a research note on Tuesday, March 13th. HC Wainwright set a $6.00 price target on shares of Aptose Biosciences and gave the stock a buy rating in a research note on Wednesday, March 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $5.50.
An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC increased its stake in Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,421 shares of the biotechnology company’s stock after buying an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Aptose Biosciences (APTO) Downgraded by Zacks Investment Research to Hold” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3301930/aptose-biosciences-apto-downgraded-by-zacks-investment-research-to-hold.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.